Genetron Health develops detection kit for COVID-19
Singapore, April 10 -- Genetron Holdings Limited (Genetron Health), a China-based precision oncology company that covers full-cycle cancer care, announces that its independently developed Detection Kit for Novel Coronavirus (SARS-CoV-2) RNA (PCR-Fluorescence Probing) has been issued CE marking and had its application accepted by FDA-EUA.
Based on the test kit, three of Genetron Health's clinical laboratories have passed the COVID-19 External Quality Assessment (EQA) by China's National Center for Clinical Laboratories (NCCL).
In addition to CE marking and FDA-EUA application acceptance, Genetron Health's nucleic acid detection kit has also performed excellently in a verification project held by the Beijing Center for Disease Prevention ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.